MBRX — Moleculin Biotech, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1659617 ·
Last close
$6.83
Market Cap
$6.96M
52W High
$106.00
52W Low
$3.13
ADV30
35,485
Next earnings
—
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -7,561,000 -7,635,000 21,087,000 7,262,000 9,500,000
Mar 2026 0 — -7,874,000 -12,845,000 23,363,000 10,317,000 8,180,000
Dec 2025 0 — -7,533,000 15,552,000 22,126,000 8,878,000 7,120,000
Sep 2025 0 — -5,906,000 -25,399,000 20,353,000 6,703,000 47,273,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-25,357,000
Investing CF
$0
Financing CF
$25,087,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-50.62
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-226,484,000
Inventory
—
Receivables
$4,000
ST Investments
—
EBIT TTM
$-28,874,000
Pretax Income TTM
$-30,327,000
Interest Exp TTM
—
Analysts
3

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -25,103,000 -33,560,000 22,126,000 7,120,000 15,006,000 -22,735,000
Dec 2024 0 -26,641,000 -26,048,000 16,925,000 5,717,000 11,208,000 -23,862,000
Dec 2023 0 -29,631,000 -29,769,000 38,217,000 12,144,000 26,073,000 -23,591,000
Dec 2022 0 -30,640,000 -29,025,000 57,422,000 5,231,000 52,191,000 -27,639,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-39,964,000
OpCashFlow TTM
—
Assets (Latest)
$21,087,000
Forward EPS
$-110.50

Peers — same industry

TickerNameMarket CapLastDaily %
IMRN Immuron Ltd $7.03M $0.87 —
XCUR EXICURE, INC. $7.07M $1.08 —
LGVN Longeveron Inc. $6.83M $2.11 —
CVKD Cadrenal Therapeutics, Inc. $6.71M $1.88 —
CURX Curanex Pharmaceuticals Inc $7.37M $4.70 —

News headlines (Yahoo Finance, 1h cache)

Moleculin Strengthens Global Intellectual Property Portfolio Around Annamycin, Secures Korean Patent Allowance
2026-11-18 13:35 · Yahoo
Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout
2026-11-16 12:30 · Yahoo
Moleculin Secures Australian Patent for Annamycin Formulation Technology
2026-11-12 13:37 · Yahoo
Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies
2026-11-10 19:45 · Yahoo
Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
2026-11-04 16:00 · Yahoo
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
2026-10-30 12:40 · Yahoo
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
2026-10-20 12:12 · Yahoo
Moleculin Announces Reverse Stock Split
2026-10-16 13:20 · Yahoo
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
2026-09-29 12:45 · Yahoo
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
2026-09-25 17:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.